Opportunities and challenges for human papillomavirus vaccination in China

Chao ZhaoYun ZhaoJingran LiMingzhu LiYujing ShiLihui Weia Gynaecology,Peking University People's Hospital,Beijing,Chinab MRL Global Medical Affairs,MSD China,Shanghai,Chinac Department of Gynecology and Obstetrics,Peking University People's Hospital
DOI: https://doi.org/10.1080/21645515.2024.2329450
2024-04-06
Human Vaccines & Immunotherapeutics
Abstract:Current estimates of the HPV infection rate in China vary by geographic region (9.6–23.6%), with two age peaks in prevalence in women ≤20–25 years of age and 50–60 years of age. HPV-16, 52 and 58 are the most commonly-detected HPV genotypes in the Chinese population. In China, five HPV vaccines are licensed and several others are undergoing clinical trials. Multiple RCTs have shown the efficacy and safety of the bvHPV (Cervarix), Escherichia coli -produced bvHPV (Cecolin), Pichia pastoris -produced bvHPV (Walrinvax), qvHPV (Gardasil) and 9vHPV (Gardasil-9) vaccines in Chinese populations, including two studies showing long-term efficacy (≥8 years) for the bvHPV and qvHPV vaccines. Real-world data from China are scarce. Although modeling studies in China show HPV vaccination is cost-effective, uptake and population coverage are relatively low. Various policies have been implemented to raise awareness and increase vaccine coverage, with the long-term aim of eliminating cervical cancer in China.
immunology,biotechnology & applied microbiology
What problem does this paper attempt to address?
The paper attempts to address the opportunities and challenges of human papillomavirus (HPV) vaccination among the Chinese population. Specifically, the paper focuses on the following aspects: 1. **Epidemiology of HPV Infection**: The paper explores the differences in HPV infection rates across different regions of China, as well as the distribution of high-risk HPV infections among women of different age groups. 2. **Effectiveness and Safety of HPV Vaccines**: The paper reviews the clinical trial results of various HPV vaccines in the Chinese population, including the long-term effectiveness and safety data of bivalent, quadrivalent, and nonavalent vaccines. 3. **Real-world Application of HPV Vaccines**: The paper discusses the real-world application effects of HPV vaccines, particularly in reducing cervical intraepithelial neoplasia (CIN) and other HPV-related diseases. 4. **Knowledge, Attitudes, and Practices of HPV Vaccination**: The paper analyzes the level of awareness, attitudes, and actual vaccination practices among the Chinese population, exploring the main barriers to vaccination, such as lack of knowledge and cost issues. 5. **Policies to Increase Vaccination Rates**: The paper introduces the policy measures taken by the Chinese government to increase HPV vaccination rates, including free vaccination pilot projects and innovative health city policies. Overall, the paper aims to comprehensively assess the current status of HPV vaccination in China, identify existing problems, and propose improvement suggestions to promote the prevention and control of cervical cancer.